title: HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know.
abstract: Patients with Systemic Lupus Erythematosus (SLE) are at increased risk for infections. Vaccination is a powerful tool to prevent infections, even in immunocompromised patients. Most non-live vaccines are immunogenic and safe in patients with SLE, even if antibody titres are frequently lower than those of healthy controls. Human papillomavirus (HPV) infections are more prevalent in SLE patients when compared to the healthy population. Low-risk types of this virus cause anogenital warts, while high risk types are strongly related to pre-malignant cervical abnormalities and cervical cancer. HPV vaccines have been developed to prevent these conditions. Although little is known about HPV vaccination in SLE, few studies in patients with autoimmune rheumatic diseases (AIRDs) have shown that HPV vaccines are safe, and capable to induce an immunogenic response in this group of patients. To date, available data suggest that HPV vaccines can be given safely to SLE patients. Given the increased incidence of cervical abnormalities due to HPV in SLE patients, this vaccination should be encouraged.
authors.affiliation: Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Room number KC 03.063.0, PO BOX 85090, 3508 AB, Utrecht, The Netherlands. I.rotsteingrein@umcutrecht.nl.|Department of Pediatric Rheumatology, Pequeno Príncipe Hospital, Curitiba, Brazil. I.rotsteingrein@umcutrecht.nl.
authors.forename: Ingrid Herta Rotstein
authors.initials: IH
authors.lastname: Grein
authors.affiliation: Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Room number KC 03.063.0, PO BOX 85090, 3508 AB, Utrecht, The Netherlands. n.groot@erasmusmc.nl.|Department of Pediatric Immunology, Sophia Children's Hospital - Erasmus MC, Rotterdam, The Netherlands. n.groot@erasmusmc.nl.
authors.forename: Noortje
authors.initials: N
authors.lastname: Groot
authors.affiliation: Department of Gynecology, University of the Estate of Rio de Janeiro, Rio de Janeiro, Brazil. marcelaiglacerda@hotmail.com.
authors.forename: Marcela Ignacchiti
authors.initials: MI
authors.lastname: Lacerda
authors.affiliation: Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Room number KC 03.063.0, PO BOX 85090, 3508 AB, Utrecht, The Netherlands. N.Wulffraat@umcutrecht.nl.
authors.forename: Nico
authors.initials: N
authors.lastname: Wulffraat
authors.affiliation: Department of Pediatric, Division of Immunology and Rheumatology, School of Medicine of Ribeirão Preto - University of São Paulo, São Paulo, Brazil. gecilmara@gmail.com.
authors.forename: Gecilmara
authors.initials: G
authors.lastname: Pileggi
mesh_terms: D052685:Alphapapillomavirus / Q000276:immunology*; D014943:Global Health; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000276:immunology; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D015995:Prevalence; D014611:Vaccination / Q000379:methods*
chemical_list: D053918:Papillomavirus Vaccines